The Scientist : Can Biotech be Generic? [20/12/2004]

Around the world, legislators are deciding if "biogenerics" pass muster

Email: Dana Wilkie - dwilkie@the-scientist.com
The Scientist 2004, 18(24):42

20 December 2004

This past spring the Novartis subsidiary, Sandoz, made a bid to sell a copycat version of human growth hormone in the European Union and was rejected, triggering a law-suit between Sandoz and the EU that is still ongoing. In October, however, Australia approved the same copycat drug, called Omnitrope, making it the world's first approval of a so-called biogeneric in a regulated market.

Password

> Forgot Password?
> FAQ
> Subscribe

Subscribing to The Scientist is easy and inexpensive.

And you can choose from many options. Try us out with an online day pass starting at only $4.95. Or, get it all with unlimited online access to The Scientist Archive and door-to-door delivery of our monthly print magazine.


	The Scientist also offers site licenses to institutions and organizations. When your librarian adds The Scientist to the library's collection, you can get unlimited online access through your place of work or study. Recommend The Scientist today